Welcome to our dedicated page for GB SCIENCES news (Ticker: GBLX), a resource for investors and traders seeking the latest updates and insights on GB SCIENCES stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GB SCIENCES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GB SCIENCES's position in the market.
Gb Sciences announced a multicomponent therapeutic for Parkinson's disease, showcasing a combination of cannabinoids that are more effective together than individually. Dr. Andrea Small-Howard emphasized that this plant-inspired treatment, which received US FDA approval, could be beneficial as a prescription drug. Current estimates indicate that about 1 million Americans suffer from Parkinson's disease, with associated costs nearing $52 billion in the U.S. The company is preparing for first-in-human studies to assess its cannabinoid formulations.
Gb Sciences showcased its proprietary drug discovery platform, PhAROS™, at the ALCOR Drug Discovery Platform Summit, emphasizing its potential in identifying plant-inspired therapeutic mixtures. President and Chief Science Officer, Dr. Andrea Small-Howard, highlighted the engagement with over 120 global companies. PhAROS™ employs AI analytics to develop therapeutic mixtures for conditions like neurological disorders and inflammation. The company has recently secured four US patents focusing on treatments for Parkinson's disease and chronic pain, enhancing its drug pipeline and future growth prospects.
Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences, emphasized the development of plant-inspired formulations as safer alternatives to opioid medications at the Pain Therapeutics Conference in London. Chronic pain affects over 20% of U.S. adults, representing a significant health burden. Gb Sciences' cannabis-inspired therapeutics are performing well in preclinical studies, and the company aims to leverage its AI-driven drug discovery platform, PhAROS™, for innovative drug development. The focus is on creating effective pain treatment options amidst rising concerns over opioid addiction.
Gb Sciences has partnered with FHI Clinical to develop a go-to-market strategy for its cannabinoid therapy targeting COVID-related cytokine release syndrome. The collaboration aims to draft a clinical trial protocol for a first-in-human trial of Gb Sciences' proprietary formulations. FHI Clinical has extensive experience with COVID trials, supporting 23 studies and currently managing 19. Gb Sciences has previously secured positive proof-of-concept data for its cannabinoid mixtures, indicating potential for immune response modulation against viral infections.
Gb Sciences has selected the University of Lethbridge for a crucial dose range study of its patent-protected formulations aimed at treating Parkinson's disease (PD). This study is a key step towards filing an Investigational New Drug Application for first-in-human clinical trials, expected next year. The Parkinson's treatment market is projected to reach $8.8 billion by 2026. Gb Sciences received a U.S. patent for its cannabinoid formulations and previous animal studies showed significant reductions in PD-like symptoms with no noted adverse effects.
Gb Sciences has co-published a study in the International Journal of Pharmaceutics on March 25, demonstrating that their proprietary nanoparticle technology enhances the efficacy of cannabis-based terpenes for pain management. This research indicates that encapsulated terpenes show significantly higher activation of TRPV1 pain receptors compared to free terpenes, suggesting potential for effective chronic pain treatment. Gb Sciences is advancing multiple preclinical programs, including a promising treatment for Parkinson's disease.
Gb Sciences (OTCQB:GBLX) has announced a strategic shift to focus solely on biopharmaceuticals, highlighted by the sale of its cannabis production facility in December 2021. This transition aims to reduce debt and leverage its biopharmaceutical pipeline, which is projected to hold significant future value. The company is preparing for its first-in-human trial for a Parkinson's disease treatment, developing prototypes in collaboration with Catalent Pharma. In addition to Parkinson's, Gb Sciences is advancing programs related to COVID-19 and chronic pain, showcasing its commitment to innovative therapeutic options.
Gb Sciences (OTCQB:GBLX) announced a significant strategic shift in its business model, transitioning to a purely biopharmaceutical focus after selling its cannabis production facility in December 2021. This decision aims to reduce debt and enhance shareholder value through its biopharmaceutical pipeline. Key developments include preparations for a first-in-human trial of a Parkinson's disease treatment, collaboration with Catalent Pharma to develop clinical prototypes, and ongoing preclinical studies for chronic pain and COVID-19 treatments. The company emphasizes its commitment to innovative therapies and advancing clinical trials.
Gb Sciences has received a new patent from the U.S. Patent and Trademark Office for cannabinoid formulations aimed at treating cardiac hypertrophy, TRPV1-receptor-associated hearing loss, and urinary cystitis. Despite existing heart medications, heart disease remains a leading cause of death in the U.S. The market for heart disease drugs is projected to reach $64 billion by 2026. Gb Sciences combines AI and plant-based therapies, having filed numerous patents, with a commitment to advancing therapeutic solutions.
Gb Sciences has garnered media attention for its collaboration with Michigan State University (MSU) following a study that suggests specific cannabinoid and terpene ratios may help treat COVID-19 symptoms. The preclinical data indicates promising results in reducing hyperinflammation. Interviews with MSU researcher Norbert Kaminski highlighted ongoing studies that require further validation. Gb Sciences' proprietary cannabinoid mixtures have shown potential in managing cytokine release syndromes linked to COVID-19. The company is focused on developing therapeutic mixtures to address the evolving challenges of viral infections.
FAQ
What is the current stock price of GB SCIENCES (GBLX)?
What is the market cap of GB SCIENCES (GBLX)?
